Abstract: A process in continuous is described for the preparation of oxides of olefins by the direct epoxidation of an olefin with hydrogen peroxide, or compounds capable of producing hydrogen peroxide under the reaction conditions, in a solvent medium, in the presence of a catalytic system consisting of a zeolite containing titanium and a nitrogenated organic base having formula (I). The process allows the production of high conversions and selectivities of the olefin into the corresponding oxide with a stable catalytic activity over a period of time.

Abstract: A titanosilicate catalyst and method for preparing the same, comprising primary titanosilicate particles which are combined with one another, wherein the titanosilicate catalyst comprises pores having a pore diameter of from 50 to 300 .ANG.. The inventive catalyst exhibits activity in a hydroxylation reaction of an aromatic compound, or an epoxidation reaction of an olefin, or an ammoximation reaction of a ketone using hydrogen peroxide as an oxidant.

Abstract: The present invention relates to novel derivatives of LL-F28249 compounds. These LL-F28249 compounds preferably are derived via a controlled microbiological fermentation of Streptomyces cyaneogriseus subspecies noncyanogenus having deposit accession number NRRL 15773. The 23-deoxy-27-halo(chloro) derivatives have the 23-hydroxy group of the LL-F28249 compounds replaced by hydrogen and a halogen such as chlorine in the 27-position with the double bond shifted to the 26,26'-position. The novel derivatives of the present invention possess activity as anthelmintic, ectoparasitic, insecticidal, acaricidal and nematicidal agents and are useful in areas of human and animal health and in agricultural crops. Compositions containing the present compounds also are presented herein.

Abstract: The present invention relates to novel derivatives of LL-F28249 compounds wherein the 23-hydroxyl group is replaced with hydrogen and the double bond at the C(26,27)-position is epoxidized concomitant with or without epoxidation of the double bond at the C(14,15)-position. The LL-F28249 compounds (collectively) are isolates from the fermentation broth of Streptomyces cyaneogriseus subspecies noncyanogenus having deposit accession number NRRL 15773. The compounds of the present invention are derived by regioselective epoxidation of 5,23-O,O-bissilylated LL-F28249 compounds at low temperature, desilylation, re-silylation of the 5-hydroxyl group, thiocarbonylation of the 23-hydroxyl group, disilyation followed by tributyltin hydride reduction. The novel deoxy compounds of the present invention have anthelmintic, insecticidal, ectoparasiticidal, nematicidal and acaricidal activity. Compositions containing these described derivatives as active ingredients thereof are described herein.

Abstract: The present invention relates to novel 23-oxo (keto) and 23-imino derivatives of certain C(26,27)-epoxy- and C(14,15;26,27)-diepoxy-LL-F28249 compounds. The LL-F28249 compounds (collectively) are isolates from the fermentation broth of Streptomyces cyaneogriseus subspecies noncyanogenus having deposit accession no. NRRL-15773. The derivatives are obtained by oxidation of the 23-hydroxy group of 5-O-silylated-C(26,27)-epoxy and C(14,15;26,27)diepoxy-LL-F28249 compounds, followed by desilylation and derivatization with amino compounds. The novel compounds have anthelmintic, ectoparasiticidal, nematicidal, insecticidal and acaricidal activity and are, therefore, useful in the treatment of infections in warm-blooded animals and infestations in agricultural crops. Compositions containing the present compounds as active ingredients thereof also are presented.

Abstract: A process for producing an alkylene oxide or mixture of alkylene oxides by a reaction which comprises reacting an olefin or mixture thereof with an oxygen-containing gas in the presence of at least one molten nitrate salt and a co-catalyst.

Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.

Abstract: Novel 3-hydroxy-3-methylglutaryl-Coenzyme A(HMG-CoA) reductase inhibitors, which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II) ##STR1## and pharmaceutically acceptable salts of the compound (II) in which Z is hydrogen are disclosed.

Abstract: A process of producing glycidyl ethers of monohydric or polyhydric phenols is disclosed, which comprises mixing a monohydric or polyhydric phenol, dioxane or diethoxyethane, and epichlorohydrin; adding to the mixture an aqueous solution of an alkali metal hydroxide and subjecting to azeotropic distillation water, dioxane or diethoxyethane, and epichlorohydrin, followed by liquefaction of the distillate to be divided into an aqueous layer and an organic layer, and circulating the organic layer to the mixture whereas eliminating the aqueous layer. According to this process, the content of hydrolyzable chlorine which cannot be removed in a subsequent purification step is minimized and the phenol glycidyl ethers thus obtained are well suited for the use of sealing materials for integrated circuits.

Abstract: Compounds having the formula ##STR1## wherein R is halogen; C.sub.1 -C.sub.2 alkyl; C.sub.1 -C.sub.2 alkoxy; nitro; cyano; C.sub.1 -C.sub.2 haloalkyl; or R.sup.a SO.sub.n --wherein n is 0 or 2 and R.sup.a is C.sub.1 -C.sub.2 alkyl; R.sup.1 is hydrogen or C.sub.1 -C.sub.4 alkyl; R.sup.2 is hydrogen or C.sub.1 -C.sub.4 alkyl; or R.sup.1 and R.sup.2 together are alkylene having 2-5 carbon atoms; R.sup.3 is hydrogen or C.sub.1 -C.sub.4 alkyl; R.sup.4 is hydrogen or C.sub.1 -C.sub.4 alkyl; or R.sup.3 and R.sup.4 together are carbonyl; and R.sup.5 and R.sup.6 independently are (1) hydrogen; (2) halogen; (3) C.sub.1 -C.sub.4 alkyl; (4) C.sub.1 -C.sub.4 alkoxy; (5) trifluoromethoxy; (6) cyano; (7) nitro; (8) C.sub.1 -C.sub.4 haloalkyl; (9) R.sup.b SO.sub.m --wherein m is the integer 0, 1 or 2; and R.sup.b is (a) C.sub.1 - C.sub.4 alkyl; (b) C.sub.1 -C.sub.4 alkyl substituted with halogen or cyano; (c) phenyl; or (d) benzyl; (10) --NR.sup.c R.sup.d wherein R.sup.c and R.sup.d independently are hydrogen or C.sub.1 -C.

Abstract: Compounds having the formula ##STR1## wherein R is halogen; C.sub.1-C.sub.2 alkyl; C.sub.1-C.sub.2 alkoxy; nitro; cyano; C.sub.1-C.sub.2 haloalkyl; or R.sup.a SO.sub.n -- wherein n is 0 or 2 and R.sup.a is C.sub.1-C.sub.2 alkyl; R.sup.1 is hydrogen or C.sub.1 -C.sub.4 alkyl; R.sup.2 is hydrogen or C.sub.1 -C.sub.4 alkyl; or R.sup.1 and R.sup.2 together are alkylene having 2-5 carbon atoms; R.sup.3 is hydrogen or C.sub.1 -C.sub.4 aklyl; R.sup.4 is hydrogen or C.sub.1 -C.sub.4 alkyl; or R.sup.3 and R.sup.4 together are carbonyl; and R.sup.5 and R.sup.6 independently are (1) hydrogen; (2) halogen; (3) C.sub.1 -C.sub.4 alkyl; (4) C.sub.1 -C.sub.4 alkoxy; (5) trifluoromethoxy; (6) cyano; (7) nitro; (8) C.sub.1 -C.sub.4 haloalkyl; (9) R.sup.b SO.sub.m -- wherein m is the integer 0, 1 or 2; and R.sup.b is (a) C.sub.1 -C.sub.4 alkyl; (b) C.sub.1 -C.sub.4 alkyl substituted with halogen or cyano; (c) phenyl; or (d) benzyl; (10) --NR.sup.c R.sup.d wherein R.sup.c and R.sup.d independently are hydrogen or C.sub.1 -C.sub.

Abstract: The present invention relates to compounds of formula I ##STR1## or a salt, ester or amide thereof; wherein R.sup.1 is --CH.sub.2 --CH.sub.2 --, CH.sub.2 --O-- or --O--CH.sub.2 --; R.sup.2 and R.sup.3 are the same or different and are each hydrogen, C.sub.1-4 alkyl or taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring having four to six ring members; R.sup.4 is a single bond or a C.sub.1-7 bivalent aliphatic hydrocarbon group and may be joined to the aromatic ring system at the 2,3,8 or 9 positions; n is 0 to 3, and their use as anithistamine and antiasthma agents.

Abstract: This invention provides process embodiments for shape-selective oxidation of cyclic ketones to lactone and/or omega-hydroxycarboxylic acid products in the presence of a zeolite catalyst composition such as ZSM-5 or zeolite Beta.Cyclohexanone can be converted to epsilon-caprolactone or 6-hydroxycaproic acid as a main product under selected conditions.

Abstract: Ascorbic acid and substituted ascorbic acids can be reacted with a tetraorganosilicate such as a tetraalkylorthosilicate to yield a product which contains silicon. The products are generally solid in nature, and typically they are insoluble without hydrolysis. The products are useful as active agents in the prevention, treatment, or delaying of the onset of calcium-related bone disease such as post-menopausal osteoporosis.

Abstract: This invention relates to a process for separating mono-n-hexylamine from water and particularly to an improvement in a process for the recovery of mono-n-hexylamine from the reaction of n-hexanol with ammonia under amination conditions. In this process water is produced as a by-product and in the separation process an azeotrope is formed which comprises about 49% water and 51% hexylamine. The process for enhancing separation of the azeotrope of mono-n-hexylamine and water comprises contacting the azeotrope of mono-n-hexylamine and water with di-n-hexylamine or with a mixture of di-n-hexylamine and tri-n-hexylamine in sufficient amount to reduce the solubility of mono-n-hexylamine in water thus forming an organic phase and an aqueous phase which can be separated by simple techniques, e.g., decanting.

Abstract: Novel poly(hydrocarbylthio)anilines are 2,4,6-trisubstituted anilines wherein the substituents in at least two of the ortho and para positions are hydrocarbylthio substituents, any other p-substituent is hydrocarbyl or hydrocarbyloxy, any other ar-substituents are chloro, fluoro, hydrocarbyl, hydrocarbyloxy, and/or hydrocarbylthio, and any N-substituents are hydrocarbyl.

Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1## and pharmaceutically acceptable salts of the compounds (II) in which Z is hydrogen are disclosed.

Abstract: Novel 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1##

Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) and (II): ##STR1##

Abstract: Novel light producing 1,2-dioxetanes are described of the formula ##STR1## wherein ArOX is an aryl ring substituted with an X oxy group and A are passive organic groups which allow the 1,2-dioxetane to produce light when triggered by removing X. X is a chemically labile group which is removed by an activating agent. The 1,2-dioxetane compounds can be triggered to produce light at room temperatures.